Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.48 |
| ▸ | HTR6 | P50406 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | MPO | P05164 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 4/20 | 0.46 |
| ▸ | CA2 | P00918 | 4/20 | 0.46 |
| ▸ | CA12 | O43570 | 3/20 | 0.46 |
| ▸ | CA9 | Q16790 | 3/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.46 |
| ▸ | CA4 | P22748 | 2/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | CA6 | P23280 | 1/20 | 0.46 |
| ▸ | CA5A | P35218 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | AGO2 | Q9UKV8 | 1/20 | 0.46 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20379865 | 0.98 | TSHR (0.46) | TSHRHTR6LMNAMPOCYP3A4 | |
| SCHEMBL31219768 | 0.96 | TSHR (0.48) | TSHRHTR6LMNAMPOCYP3A4 | |
| SCHEMBL2149410 | 0.91 | TSHR (0.52) | TSHRHTR6LMNAMPOCYP3A4 | |
| SCHEMBL14501834 | 0.84 | HTR6 (0.40) | TSHRHTR6LMNAMPOCYP3A4 | |
| SCHEMBL1865965 | 0.82 | HTR6 (0.44) | TSHRHTR6LMNAMPOCYP3A4 | |
| SCHEMBL2632976 | 0.82 | DDIT3 (0.44) | TSHRHTR6LMNAMPOCYP3A4 | |
| SCHEMBL14538027 | 0.80 | NAMPT (0.46) | TSHRHTR6ALDH1A1NT5EGAA | |
| SCHEMBL2924761 | 0.79 | LMNA (0.46) | LMNACA1CA2CA12CA9 | |
| SCHEMBL217625 | 0.79 | ALDH1A1 (0.48) | LMNACYP3A4CYP2C9CA1CA2 | |
| SCHEMBL1268648 | 0.79 | MMP13 (0.45) | PIP4K2APIK3C3MMP8MMP13MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2342185-B1 | SULFON SUBSTITUTED ANILINE PYRIMIDINE DERIVATIVES AS CDK INHIBITORS, THEIR MANUFACTURE AND USE AS MEDICINE | BAYER IP GMBH (DE) | 2016-01-13 | — | — | EP | disclosed |
| US-9091922-B2 | Resin composition, resist underlayer film, resist underlayer film-forming method and pattern-forming method | JSR CORPORATION (JP) | 2015-07-28 | — | — | US | disclosed |
| US-8802686-B2 | Sulfone-substituted anilinopyrimidine derivatives as CDK inhibitors, the production thereof, and use as a medicine | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-08-12 | — | — | US | disclosed |
| US-20140014620-A9 | RESIN COMPOSITION, RESIST UNDERLAYER FILM, RESIST UNDERLAYER FILM-FORMING METHOD AND PATTERN-FORMING METHOD | JSR CORPORATION (JP) | 2014-01-16 | — | — | US | disclosed |
| US-20130153535-A1 | RESIN COMPOSITION, RESIST UNDERLAYER FILM, RESIST UNDERLAYER FILM-FORMING METHOD AND PATTERN-FORMING METHOD | JSR CORPORATION (JP) | 2013-06-20 | — | — | US | disclosed |
| EP-1944305-B1 | Quinoline derivatives as phosphodiesterase inhibitors | GLAXO GROUP LTD (GB) | 2011-10-19 | — | — | EP | disclosed |
| US-20110251222-A1 | SULFONE-SUBSTITUTED ANILINOPYRIMIDINE DERIVATIVES AS CDK INHIBITORS, THE PRODUCTION THEREOF, AND USE AS A MEDICINE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-10-13 | — | — | US | disclosed |
| US-20110230467-A1 | 4,6-DIAMINONICOTINAMIDE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-09-22 | — | — | US | disclosed |
| US-20110230467-A1 | 4,6-DIAMINONICOTINAMIDE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-09-22 | — | — | US | disclosed |
| EP-2361902-A1 | 4,6-DIAMINONICOTINAMIDE COMPOUND | Astellas Pharma Inc. (JP) | 2011-08-31 | — | — | EP | disclosed |
| EP-1633748-B1 | QUINOLINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS | GLAXO GROUP LTD (GB) | 2008-03-05 | — | — | EP | disclosed |
| EP-1633748-B1 | QUINOLINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS | GLAXO GROUP LTD (GB) | 2008-03-05 | — | — | EP | disclosed |
| US-20070142373-A1 | Quinoline derivatives as phosphodiesterase inhibitors | GLAXO GROUP LIMITED (GB) | 2007-06-21 | — | — | US | disclosed |
| US-20070142373-A1 | Quinoline derivatives as phosphodiesterase inhibitors | GLAXO GROUP LIMITED (GB) | 2007-06-21 | — | — | US | disclosed |
| US-20070142373-A1 | Quinoline derivatives as phosphodiesterase inhibitors | GLAXO GROUP LIMITED (GB) | 2007-06-21 | — | — | US | disclosed |
| US-20070049570-A1 | Quinoline derivatives as phosphodiesterase inhibitors | DEAN ANTHONY W | 2007-03-01 | — | — | US | disclosed |
| US-20070049570-A1 | Quinoline derivatives as phosphodiesterase inhibitors | DEAN ANTHONY W | 2007-03-01 | — | — | US | disclosed |
| US-20070049570-A1 | Quinoline derivatives as phosphodiesterase inhibitors | DEAN ANTHONY W | 2007-03-01 | — | — | US | disclosed |
| US-20060178416-A1 | Quinoline derivatives as phosphodiesterase inhibitors | BARKER MICHAEL D | 2006-08-10 | — | — | US | disclosed |
| WO-2004103998-A1 | QUINOLINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2004-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230467-A1 | 4,6-DIAMINONICOTINAMIDE COMPOUND | JAK3, JAK2, JAK1 | TSHR 1880/4885HTR6 863/4885LMNA 4693/4885 |
| US-20060178416-A1 | Quinoline derivatives as phosphodiesterase inhibitors | PDE3B, PDE4B, PDE4A | TSHR 2526/4885HTR6 1226/4885LMNA 2744/4885 |
| US-20110251222-A1 | SULFONE-SUBSTITUTED ANILINOPYRIMIDINE DERIVATIVES AS CDK INHIBITORS, THE PRODUCTION THEREOF, AND USE AS A MEDICINE | CDK6, CDK4, CDK2 | TSHR 3730/4885HTR6 2884/4885LMNA 3428/4885 |
| US-20070049570-A1 | Quinoline derivatives as phosphodiesterase inhibitors | PDE3B, PDE4B, PDE4A | TSHR 2526/4885HTR6 1226/4885LMNA 2744/4885 |
| US-20070142373-A1 | Quinoline derivatives as phosphodiesterase inhibitors | PDE3B, PDE4B, PDE4A | TSHR 2526/4885HTR6 1226/4885LMNA 2744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.